Our top pick for
Galmed Pharmaceuticals Ltd is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Galmed Pharmaceuticals employs 17 staff and has a market cap (total outstanding shares value) of USD$86.8 million.
|52-week range||USD$2.96 - USD$6.2|
|50-day moving average||USD$4.0324|
|200-day moving average||USD$3.8453|
|Wall St. target price||USD$17.8|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.585|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-25.21%|
|Return on equity TTM||-40.86%|
|Market capitalisation||USD$86.8 million|
TTM: trailing 12 months
There are currently 37,745 Galmed Pharmaceuticals shares held short by investors – that's known as Galmed Pharmaceuticals's "short interest". This figure is 49.1% up from 25,317 last month.
There are a few different ways that this level of interest in shorting Galmed Pharmaceuticals shares can be evaluated.
Galmed Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Galmed Pharmaceuticals shares currently shorted divided by the average quantity of Galmed Pharmaceuticals shares traded daily (recently around 157270.83333333). Galmed Pharmaceuticals's SIR currently stands at 0.24. In other words for every 100,000 Galmed Pharmaceuticals shares traded daily on the market, roughly 240 shares are currently held short.
However Galmed Pharmaceuticals's short interest can also be evaluated against the total number of Galmed Pharmaceuticals shares, or, against the total number of tradable Galmed Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Galmed Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Galmed Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0021% of the tradable shares (for every 100,000 tradable Galmed Pharmaceuticals shares, roughly 2 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Galmed Pharmaceuticals.
Find out more about how you can short Galmed Pharmaceuticals stock.
We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $2.96 up to $6.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 2.206. This would suggest that Galmed Pharmaceuticals's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.